Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 5c, provides guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of $0.16, $0.05 better than the analyst estimate of $0.11. Revenue for the quarter came in at $62.5 million versus the consensus estimate of $62.55 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2025 revenue of $250-260 million, versus the consensus of $258.6 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• United Community Banks (UCB) PT Raised to at Piper Sandler Amid 'Several Key Strategic Initiatives'
• GameSquare to acquire FanEngine assets in ~$15.9M stock deal